Upcoming Global Web Symposia
October 2, 201311:00 am to 12:00 pm EDT
Symposium Course Description:
Preclinical profiling programs for novel anti-cancer agents increasingly rely on three dimensional cell culture assays as an important tool for predicting tumor response in vivo. Patient derived tumor xenografts (PDXs) are the preferred tumor models for in vivo efficacy studies in rodents. Oncotest is a pioneer and leader in CRO services with PDXs and has the expertise to combine 350 PDXs with 3D cell culture assay technology, enabling the use of the same PDXs in 3D assays and in subsequent in vivo efficacy tests.
In this webinar Dr. Torsten Giesemann of Oncotest will introduce the 3D tumor clonogenic assay technology and Oncotest’s service offering. Dr. Ralph Tiedt of Novartis will present results of a 3D assay study executed by Oncotest.
Who Should Attend:
11:00 – 11:15 The Oncotest 3D assay: technology and services overview, Dr. Torsten Giesemann – Oncotest GmbH
11:15 – 11:30 Assessment of the anti-tumor efficacy of a c-Met inhibitor using a tumor clonogenic assay, Dr. Ralph Tiedt – Novartis Institutes for BioMedical Research
Ph.D., Head of Cell Biology and Compound Screening, Oncotest GmbH, Germany
Ph.D., Investigator III, Disease Area Oncology, Novartis Institutes for BioMedical Research
Ph.D., Product Manager, Project Management, Oncotest GmbH
250 First Avenue Suite 300Needham, MA 02494P: 781.972.5400F: 781.972.5425E: email@example.com
biological therapeutic productsbiomarkers & diagnosticsbiopharma strategybioprocess & manufacturingchemistryclinical trials & translational medicinedrug & device safety
drug discovery & developmentdrug targetsgenomicshealthcareit & informaticstechnology & tools for life sciencetherapeutic indications
conferencesreportsbarnett educational servicesconsultingpublications & eNewslettersprofessional services
executive teamtestimonialschi timelinemailing listcareers